There is interest in expanding the therapeutic application of PDE4 inhibitors to metabolic disorders, as their chronic application induces weight loss in patients and animals and improves glucose handling in mouse models of obesity and diabetes. The gene discussed is PDE4A; the disease is obesity due to melanocortin 4 receptor deficiency.